IT stocks · Small cap · NSE
Inventurus Knowledge Solutions (IKS) is a care enablement platform focused on delegating healthcare chores. With the TruBridge acquisition, it's building an integrated system of action and record for the rural and community market, complementing its comprehensive platform for large medical groups. Aims for clinical and financial sustainability.
MACD − · sector +19.3pp vs Nifty 500 (3M)
Latest FPI flow is positive, but a second consecutive positive fortnight is still required. View sector evidence
Adjusted completed-session prices, rebased to 100
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Revenue +20.8% · PAT +27.6% YoY
Price trend and sector-relative-strength timing.
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Financial-only signal; management claim evidence is not sufficient yet.
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Rev +21% YoY · PAT +28% YoY · operating leverage · margin compression
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹894 Cr | +20.8% | +4.2% |
| EBITDA | ₹290 Cr | +21.8% | -1.7% |
| Operating margin | 32.0% | +0 bps | -200 bps |
| PAT | ₹194 Cr | +27.6% | -5.8% |
| PAT margin | 21.7% | +116 bps | -231 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Updated 21/10/2026
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Trend is weak — long-term trend down. RSI 34.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
U-Score 58 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Top U-Score contributors and drags from the latest stored fundamentals.
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
12 stored score snapshots. Latest stored move: +0 points.
Business-comparable peers in IT — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Growth engines, risks, management commitments and evidence-backed delivery
Q1 FY27 revenue grew 21% YoY (12% CC) to INR893 crores. Adjusted EBITDA reached 35% (INR314 crores) after one-time acquisition costs. PAT increased 28% YoY to INR193 crores, driven by operational efficiencies and non-linearity in revenue vs. people growth.
IKS delivered strong Q1 FY27 results with healthy revenue growth and robust adjusted EBITDA margins. The TruBridge acquisition is progressing, with management reiterating FY30 EBITDA targets and outlining clear integration and AI strategies, despite an initial revenue base reset for TruBridge.
Building the only truly integrated system of action and system of record for the rural and community market (2,100+ hospitals) with TruBridge.
Leveraging TruBridge's 5M+ patient dataset to train proprietary Small Language Models (SLMs) to reduce reliance on expensive commercial LLMs.
Pivot to a land-and-expand approach for large health systems is yielding significant wins, like Advocate Health Care's expanded partnership.
Significant cross-sell opportunity into TruBridge's customer base for IKS's system of action, driving future growth.
Operating headcount is slightly inflated due to anticipated TruBridge integration, with investments to elevate performance for some TruBridge RCM customers.
Overall market growing at ~8%, outsourced TAM growing at ~12%, now expanded by the rural health system market.
Partnerships with large health systems (e.g., California system) and independent TruBridge collaborations are strengthening ties with Epic.
Patent approved for AAW model, predicting patient behavior for scheduling optimization and propensity to pay, deployed in MyCareHub.
Case study with Axia Women's Health showed $12 million cash impact through optimized coding with 96% accuracy, reducing denials.
TruBridge's operating revenue is expected to be $300M/year, down from $340M, due to conservative revenue recognition, elimination of unprofitable services, and customer discounts.
One-time acquisition expenses of INR20 crores in Q1 FY27, with similar integration expenses likely to continue into Q2 FY27.
Management acknowledges 'a lot of work to do to realize it effectively' and 'a lot of integration to do right now' for TruBridge.
Commercial Large Language Models are 'extremely expensive. The token cost is hard to justify over a period of time,' driving the need for proprietary SLMs.
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
YoY comparison is crucial for assessing overall growth and profitability trends, especially for a full fiscal year's quarter. QoQ is important to understand sequential momentum, the impact of one-time acquisition costs, and the underlying operational improvements.
12% year-on-year growth for fiscal Q1.
33% reported EBITDA (INR294 crores), approximately 200 bps higher (35% or INR314 crores) when adjusted for INR20 crores one-time exceptional TruBridge acquisition costs.
28% year-on-year, coming in at INR193 crores.
Continues to grow at a very healthy pace, given technology transformation and continuous deployment of automation.
Reiterates True North objective of at least INR3,000 crores in EBITDA by FY'30, without significant equity dilution (outside ESOPs) and returning to pre-TruBridge net debt.
Aspiration to grow the legacy IKS business ($388M annualized) at 12%+ constant currency, driving non-linearity in profitability.
Plan to transform TruBridge's operating model to achieve early-to-mid 30s EBITDA margins over the next couple of years, leveraging technology and offshore human-in-the-loop.
Committed to building a single institutionalized, outcome-oriented culture across the combined 16,000+ employees and 2,000 clients.
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| TruBridge Growth Potential | Still wrapping head around what the TruBridge growth potential is. | Management expects to articulate the growth outlook for the TruBridge book after 2-3 quarters of integration. |
| Blended EBITDA Margin | Pro forma drop post-consolidation to 26%-27% range (from 35% for legacy IKS). | Progress towards getting back to early-to-mid 30% EBITDA margins for the combined business over the next couple of years. |
| AI Token Utilization | Commercial LLMs are expensive. | Emergence of metrics on token utilization reduction from the deployment of proprietary SLMs and hierarchical AI models. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 98th percentile of the scored universe and 97th percentile within IT. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
overall median 67 · IT: 97th pctile, median 69 · Small: 99th pctile, median 66
65 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Latest exchange and company disclosures found within the past two years.
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse